| 查看: 240 | 回复: 0 | |||
[交流]
Nature Biotechnology上最新的一篇HCV治疗的文章不错
|
|
http://www.nature.com/nbt/journa ... WT.ec_id=NBT-201111 Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus Ann D Kwong, Robert S Kauffman, Patricia Hurter & Peter Mueller AffiliationsCorresponding author Nature Biotechnology 29, 993–1003 (2011) doi:10.1038/nbt.2020 Published online 08 November 2011 Infection with hepatitis C virus (HCV) is a major medical problem with over 170 million people infected worldwide. Substantial morbidity and mortality are associated with hepatic manifestations (cirrhosis and hepatocellular carcinoma), which develop with increasing frequency in people infected with HCV for more than 20 years. Less well known is the burden of HCV disease associated with extrahepatic manifestations (diabetes, B-cell proliferative disorders, depression, cognitive disorders, arthritis and Sjögren's syndrome). For patients infected with genotype 1 HCV, treatment with polyethylene glycol decorated interferon (peginterferon) α and ribavirin (PR) is associated with a low (40–50%) success rate, substantial treatment-limiting side effects and a long (48-week) duration of treatment. In the past 15 years, major scientific advances have enabled the development of new classes of HCV therapy, the direct-acting antiviral agents, also known as specifically targeted antiviral therapy for hepatitis C (STAT-C). In combination with PR, the HCV NS3-4A protease inhibitor telaprevir has recently been approved for treatment of genotype 1 chronic HCV in the United States, Canada, European Union and Japan. Compared with PR, telaprevir combination therapy offers significantly improved viral cure rates and the possibility of shortened treatment duration for diverse patient populations. Developers of innovative drugs have to blaze a new path with few validated sign posts to guide the way. Indeed, telaprevir's development was once put on hold because of its performance in a standard IC50 assay. Data from new hypotheses and novel experiments were required to justify further investment and reduce risk that the drug might fail in the clinic. In addition, the poor drug-like properties of telaprevir were a formidable hurdle, which the manufacturing and formulation teams had to overcome to make the drug. Finally, novel clinical trial designs were developed to improve efficacy and shorten treatment in parallel instead of sequentially. Lessons learned from the development of telaprevir suggest that makers of innovative medicines cannot rely solely on traditional drug discovery metrics, but must develop innovative, scientifically guided pathways for success. |
回复此楼» 猜你喜欢
透明质酸 甲基丙烯酸酐
已经有0人回复
-
305材料专硕调剂
已经有12人回复
-
药理学论文润色/翻译怎么收费?
已经有233人回复
-
[求助] 流式死活染 & 单细胞门控设置被质疑，如何优化并解释？
已经有1人回复
-
蛋白稳定性实验与功能实验不一致
已经有11人回复
-
第4年了，马上40了，可能我与国基确实无缘吧。。。
已经有12人回复
-
2026年申博药学专业
已经有1人回复
-
CSC改派-博士生交流访学
已经有19人回复
-
中山大学-第七医院-招科研助理1名（基因设计和克隆、RNA合成）
已经有0人回复
-
中山大学-第七医院-招科研助理1名（基因设计和克隆、RNA合成）
已经有1人回复
-
巴黎萨克雷大学与国家留学基金委合作博士研究生项目-脂质纳米药物/生物材料/多酚递送
已经有10人回复
找到一些相关的精华帖子，希望有用哦~
nature出版集团旗下的两本开放获取期刊：居家旅行、杀人越货之忽悠利器
已经有22人回复
- 向ASME Journal of Applied Mechanics投了一篇文章
已经有5人回复
- 最新量子模拟相关20120426Nature文章一篇
已经有35人回复
- 怎么下载一篇道客巴巴的文章，要100积分的？求助？！！！！
已经有6人回复
- 杨样在Nature Photonics 上的两篇新文章，一篇综述，一篇叠层效率创纪录8.6%
已经有84人回复
- 最新《摩擦学快报》上一篇关于石墨烯提高人造关节材料耐磨性的文章
已经有88人回复
- 《Nature》最新文章--怎样申请基金（Nature编辑亲自撰写）
已经有940人回复
- nature 20110922最新文章《可用于HIV/艾滋病治疗的中和抗体》
已经有10人回复
- 文章给修改，遇到点问题，不知道怎么回答，向版上的兄弟姐妹请教！！
已经有7人回复
- 一篇文章外审三个专家中有一个不同意，两个同意发表，怎么办？
已经有19人回复
点击这里搜索更多相关资源科研从小木虫开始，人人为我，我为人人
10